How we diagnose and treat iron deficiency anemia

It is estimated that one‐third of the world's population is anemic, the majority being due to iron deficiency (ID). In adults, ID is associated with fatigue in the absence of anemia, restless legs syndrome, pica and, in neonates, delayed growth and development. In adolescents, ID is associated with decrements in learning and behavioral abnormalities. In the absence of a clear cause, search for a source of bleeding is indicated. No single test is diagnostic of ID unless the serum ferritin is low or the percent transferrin saturation is low with an elevated total iron binding capacity. Oral iron is considered front line therapy except for conditions such as gastric bypass, heavy uterine bleeding, inflammatory bowel disease, and hereditary hemorrhagic telangiectasia. Oral iron has many unpleasant side effects, resulting in low patient adherence. For patients intolerant of, or unresponsive to, oral iron, intravenous (IV) administration is the preferred route. While early formulations were associated with a high incidence of serious adverse events (SAEs), newer formulations are much safer with SAEs occurring very infrequently. Full replacement doses can be administered in a matter of minutes to a few hours. Nevertheless, there remains a reluctance to use IV iron due to a misunderstanding of the safety of the available formulations. IV iron is safe and effective in all clinical circumstances including pregnancy. The preponderance of published evidence suggests IV iron therapy is underutilized and we believe that IV iron should be moved forward in the treatment of ID and iron deficiency anemia (IDA). Am. J. Hematol. 91:31–38, 2016. © 2015 Wiley Periodicals, Inc.

[1]  P. Kalra,et al.  A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  L. Thomsen,et al.  Intravenous iron isomaltoside 1000 (Monofer®) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial) , 2015, Vox sanguinis.

[3]  J. Powell,et al.  Ferrous Sulfate Supplementation Causes Significant Gastrointestinal Side-Effects in Adults: A Systematic Review and Meta-Analysis , 2015, PloS one.

[4]  A. Bircher,et al.  Hypersensitivity from intravenous iron products. , 2014, Immunology and allergy clinics of North America.

[5]  B. Favrat,et al.  Evaluation of a Single Dose of Ferric Carboxymaltose in Fatigued, Iron-Deficient Women – PREFER a Randomized, Placebo-Controlled Study , 2014, PloS one.

[6]  I. Macdougall,et al.  A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[7]  Y. Akın,et al.  Impact of iron supplementation on sexual dysfunction of women with iron deficiency anemia in short term: a preliminary study. , 2014, The journal of sexual medicine.

[8]  L. F. Allen,et al.  A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy , 2014, American journal of hematology.

[9]  Seth R Flaxman,et al.  A systematic analysis of global anemia burden from 1990 to 2010. , 2014, Blood.

[10]  W. Strauss,et al.  Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min , 2013, American journal of hematology.

[11]  W. Reinisch,et al.  A Randomized, Open-Label, Non-Inferiority Study of Intravenous Iron Isomaltoside 1,000 (Monofer) Compared With Oral Iron for Treatment of Anemia in IBD (PROCEED) , 2013, The American Journal of Gastroenterology.

[12]  W. Ondo,et al.  Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome. , 2013, Mayo Clinic proceedings.

[13]  J. McClung,et al.  Iron nutrition and premenopausal women: effects of poor iron status on physical and neuropsychological performance. , 2013, Annual review of nutrition.

[14]  Alan R. Ellis,et al.  The comparative short-term effectiveness of iron dosing and formulations in US hemodialysis patients. , 2013, The American journal of medicine.

[15]  B. Biggs,et al.  Control of iron deficiency anemia in low- and middle-income countries. , 2013, Blood.

[16]  N. Hevelone,et al.  Comparative rates of adverse events with different formulations of intravenous iron , 2012, American journal of hematology.

[17]  O. Irion,et al.  Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose , 2012, Journal of perinatal medicine.

[18]  Alissa Westerlund,et al.  Iron deficiency in infancy is associated with altered neural correlates of recognition memory at 10 years. , 2012, The Journal of pediatrics.

[19]  B. Myers,et al.  Comparative efficacy and safety of intravenous ferric carboxymaltose (Ferinject) and iron(III) hydroxide dextran (Cosmofer) in pregnancy , 2012, Obstetric medicine.

[20]  N. Dahl,et al.  Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia , 2011, American journal of hematology.

[21]  U. Kolb,et al.  A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[22]  M. Auerbach,et al.  Clinical use of intravenous iron: administration, efficacy, and safety. , 2010, Hematology. American Society of Hematology. Education Program.

[23]  Catherine M. Dormitzer,et al.  Use of parenteral iron products and serious anaphylactic‐type reactions , 2010, American journal of hematology.

[24]  D. Coyne,et al.  Intravenous iron: From anathema to standard of care , 2008, American journal of hematology.

[25]  J. Glaspy,et al.  Clinical update: intravenous iron for anaemia , 2007, The Lancet.

[26]  J. Critchley,et al.  Adverse events associated with intravenous iron infusion (low-molecular-weight iron dextran and iron sucrose): a systematic review , 2007 .

[27]  S. Bhandari,et al.  Tolerability and efficacy of parenteral iron therapy in hemodialysis patients, a comparison of preparations , 2007 .

[28]  M. Sipahioğlu,et al.  Is There a Difference between the Allergic Potencies of the Iron Sucrose and Low Molecular Weight Iron Dextran? , 2007, Renal failure.

[29]  C. Gasche,et al.  Systematic review: managing anaemia in Crohn's disease , 2006, Alimentary pharmacology & therapeutics.

[30]  W. Bergfeld,et al.  The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. , 2006, Journal of the American Academy of Dermatology.

[31]  G. Chertow,et al.  Update on adverse drug events associated with parenteral iron. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[32]  V. Eclache,et al.  Pica and food craving in patients with iron-deficiency anemia: a case-control study in France. , 2005, The American journal of medicine.

[33]  B. Danielson Structure, chemistry, and pharmacokinetics of intravenous iron agents. , 2004, Journal of the American Society of Nephrology : JASN.

[34]  R. Stoltzfus Iron Deficiency: Global Prevalence and Consequences , 2003, Food and nutrition bulletin.

[35]  C. Crowther,et al.  Efficacy and tolerability of low-dose iron supplements during pregnancy: a randomized controlled trial. , 2003, The American journal of clinical nutrition.

[36]  J. Cook,et al.  The quantitative assessment of body iron. , 2003, Blood.

[37]  A. Nissenson,et al.  Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. , 2002, Kidney international.

[38]  I. Macdougall,et al.  Intravenous iron sucrose: establishing a safe dose. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[39]  J. Haas,et al.  Iron-Deficiency Anemia: Reexamining the Nature and Magnitude of the Public Health Problem Iron Deficiency and Reduced Work Capacity: A Critical Review of the Research to Determine a Causal Relationship 1,2 , 2001 .

[40]  E. Barton,et al.  Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation. , 2000, The American journal of medicine.

[41]  E. Simpson,et al.  Pica during pregnancy in low-income women born in Mexico. , 2000, The Western journal of medicine.

[42]  J. Beard Effectiveness and strategies of iron supplementation during pregnancy. , 2000, The American journal of clinical nutrition.

[43]  D. Brewster,et al.  An iron treatment trial in an Aboriginal community: Improving non‐adherence , 1999, Journal of paediatrics and child health.

[44]  M. Auerbach,et al.  Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial. , 1998, The Journal of laboratory and clinical medicine.

[45]  W. Reinisch,et al.  Intravenous Iron and Erythropoietin for Anemia Associated with Crohn Disease , 1997, Annals of Internal Medicine.

[46]  K. Punnonen,et al.  Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. , 1997, Blood.

[47]  S. Fishbane,et al.  The safety of intravenous iron dextran in hemodialysis patients. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[48]  R. Lerner,et al.  Clinical use of the total dose intravenous infusion of iron dextran. , 1988, The Journal of laboratory and clinical medicine.

[49]  W. Crosby Whatever became of chlorosis? , 1987, JAMA.

[50]  J. Adamson,et al.  Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. , 1987, The New England journal of medicine.

[51]  R. Hamstra,et al.  Intravenous iron dextran in clinical medicine. , 1980, JAMA.

[52]  P. Kopelman Raised mean cell volume and meningoencephalitis associated with Mycoplasma pneumoniae infection. , 1977, British medical journal.

[53]  V. S. Nadig,et al.  Comparative therapeutic study of T.D.I. and I.M. injections of iron dextran complex in anaemia. , 1973, The Journal of the Association of Physicians of India.

[54]  K. Varde TREATMENT OF 300 CASES OF IRON DEFICIENCY OF PREGNANCY BY TOTAL DOSE INFUSION OF IRON-DEXTRAN COMPLEX. , 1965, The Journal of obstetrics and gynaecology of the British Commonwealth.

[55]  R. Wallerstein,et al.  THE TREATMENT OF IRON-DEFICIENCY ANEMIA WITH INTRAVENOUS IRON DEXTRAN. , 1964, Blood.

[56]  I. Baird,et al.  Intramuscular iron therapy in iron-deficiency anaemia. , 1954, Lancet.

[57]  J. Howell,et al.  Syndrome of anemia, dysphagia and glossitis (Plummer Vinson syndrome). , 1953, The New England journal of medicine.

[58]  J. Nissim Intravenous administration of iron. , 1947, Lancet.

[59]  C. Moore,et al.  Observations on the effect of massive doses of iron given intravenously to patients with hypochromic anemia. , 1946, Proceedings [of the] annual meeting. Central Society for Clinical Research.

[60]  R. Stockman The Treatment of Chlorosis by Iron and some Other Drugs , 1893, British medical journal.

[61]  L. Leibovici,et al.  The safety of intravenous iron preparations: systematic review and meta-analysis. , 2015, Mayo Clinic proceedings.

[62]  J. Winchester,et al.  A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[63]  T. Bothwell,et al.  Iron absorption. I. Factors influencing absorption. , 1958, The Journal of laboratory and clinical medicine.